Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M9FQ
|
|||
| Former ID |
DNCL001869
|
|||
| Drug Name |
PF-489791
|
|||
| Synonyms |
UNII-2S27T3DSZ3; PF-489791; PF-00489791; 853003-48-2; 2S27T3DSZ3; PF-489,791; ZUHZNKJIJDAJFD-UHFFFAOYSA-N; UK-489,791; SCHEMBL331279; SCHEMBL8042129; GTPL8377; DB11736; SB16722; 1H-Pyrazolo(4,3-d)pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-((4-methyl-2-pyridinyl)amino)-N-(methylsulfonyl); n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Phase 2 | [1] | |
| Raynaud disease [ICD-11: BD42.0; ICD-10: I73, I73.0] | Phase 2 | [1] | ||
| Company |
Pfizer New York, NY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H28N8O4S
|
|||
| Canonical SMILES |
CCN(C)C1=NC2=C(C(=N1)NC3=NC=CC(=C3)C)N(N=C2C(=O)NS(=O)(=O)C)CCOCC
|
|||
| InChI |
1S/C20H28N8O4S/c1-6-27(4)20-23-15-16(19(29)26-33(5,30)31)25-28(10-11-32-7-2)17(15)18(24-20)22-14-12-13(3)8-9-21-14/h8-9,12H,6-7,10-11H2,1-5H3,(H,26,29)(H,21,22,23,24)
|
|||
| InChIKey |
ZUHZNKJIJDAJFD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 853003-48-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 5A (PDE5A) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | cGMP effects | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025495) | |||
| REF 2 | Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.